TW252046B - - Google Patents

Info

Publication number
TW252046B
TW252046B TW082109868A TW82109868A TW252046B TW 252046 B TW252046 B TW 252046B TW 082109868 A TW082109868 A TW 082109868A TW 82109868 A TW82109868 A TW 82109868A TW 252046 B TW252046 B TW 252046B
Authority
TW
Taiwan
Application number
TW082109868A
Other languages
Chinese (zh)
Original Assignee
Boehringer Ingelheim Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Kg filed Critical Boehringer Ingelheim Kg
Application granted granted Critical
Publication of TW252046B publication Critical patent/TW252046B/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44Oxidoreductases (1)
    • A61K38/446Superoxide dismutase (1.15)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004Oxidoreductases (1.)
    • C12N9/0089Oxidoreductases (1.) acting on superoxide as acceptor (1.15)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y115/00Oxidoreductases acting on superoxide as acceptor (1.15)
    • C12Y115/01Oxidoreductases acting on superoxide as acceptor (1.15) with NAD or NADP as acceptor (1.15.1)
    • C12Y115/01001Superoxide dismutase (1.15.1.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
TW082109868A 1992-11-27 1993-11-23 TW252046B (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4239877A DE4239877C1 (de) 1992-11-27 1992-11-27 Stabilisierte Superoxid-Dismutase (SOD)-Zusammensetzung

Publications (1)

Publication Number Publication Date
TW252046B true TW252046B (pl) 1995-07-21

Family

ID=6473780

Family Applications (1)

Application Number Title Priority Date Filing Date
TW082109868A TW252046B (pl) 1992-11-27 1993-11-23

Country Status (16)

Country Link
US (1) US5464614A (pl)
EP (1) EP0599262A3 (pl)
JP (1) JPH06199691A (pl)
KR (1) KR940011014A (pl)
AU (1) AU671495B2 (pl)
CA (1) CA2110087A1 (pl)
DE (1) DE4239877C1 (pl)
FI (1) FI935264A (pl)
HU (1) HUT65580A (pl)
IL (1) IL107754A (pl)
MX (1) MX9307433A (pl)
NO (1) NO934289L (pl)
NZ (1) NZ250285A (pl)
PH (1) PH30788A (pl)
TW (1) TW252046B (pl)
ZA (1) ZA938848B (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2719479B1 (fr) * 1994-05-04 1996-07-26 Sanofi Elf Formulation stable lyophilisée comprenant une protéine: kit de dosage.
US5876992A (en) * 1996-07-03 1999-03-02 Molecular Biology Resources, Inc. Method and formulation for stabilization of enzymes
US6132712A (en) * 1996-12-11 2000-10-17 A. Glenn Braswell Superoxide dismutase stabilized with fragments of casein and pharmaceutical compositions incorporating same
IL130967A0 (en) * 1997-01-30 2001-01-28 Hoechst Marion Roussel Ltd Freeze-dried composition of bone morphogenetic protein human mp52
US20040132653A1 (en) * 1997-01-30 2004-07-08 Biopharm Gmbh Lyophilized composition of bone morphogenetic factor human MP52
AU2002310497A1 (en) * 2001-06-20 2003-01-08 Caprion Pharmaceuticals Inc. Protein aggregation assays and uses thereof
DE10223783A1 (de) * 2002-05-29 2003-12-11 Boehringer Ingelheim Pharma Neue Formulierung zur parenteralen Applikation eines Na-Kanal-Blockers
EP1692187B1 (en) * 2003-10-31 2012-06-27 Tae-Yoon Kim EC SOD and cell transducing EC SOD and use thereof
US8318803B2 (en) * 2003-10-31 2012-11-27 Tae-Yoon Kim EC SOD and use thereof
KR101010055B1 (ko) * 2008-06-16 2011-01-21 한국전력공사 디스크 유량계 및 그의 제어방법
WO2011041584A2 (en) 2009-09-30 2011-04-07 President And Fellows Of Harvard College Methods for modulation of autophagy through the modulation of autophagy-enhancing gene products
AU2013336279B2 (en) * 2012-10-26 2018-07-19 Lupin Limited Stable pharmaceutical composition of TNFR:Fc fusion protein
EP3091069A1 (en) * 2015-05-06 2016-11-09 Fitoplancton Marino S.L. Method for obtaining a biomass of a microalga of the species tetraselmis chuii enriched in superoxide dismutase (sod)

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5712993A (en) * 1980-06-23 1982-01-22 Fujirebio Inc Isolation of superoxide dismutase
IT1142524B (it) * 1981-05-27 1986-10-08 Serono Ist Farm Composizione farmaceutica contenente orgoteina
DE3273597D1 (en) * 1981-11-28 1986-11-06 Sunstar Kk Pharmaceutical composition containing interferon in stable state
US4447355A (en) * 1982-04-07 1984-05-08 Asahi Kasei Kogyo Kabushiki Kaisha Method for stabilizing a tumor necrosis factor and a stable aqueous solution or powder containing the same
EP0123291A2 (en) * 1983-04-20 1984-10-31 Kyowa Hakko Kogyo Co., Ltd. Method for stabilizing interferon
EP0656418B1 (en) * 1983-10-03 2002-12-04 Chiron Corporation Superoxide dismutase and expression in microorganisms
JPS60155133A (ja) * 1983-11-09 1985-08-15 シンビオテイツクス コ−ポレイシヨン アンチ−イデイオタイプのモノクロナル抗体を採用したアンチ−イデイオタイプワクチン
JPS60228422A (ja) * 1984-04-26 1985-11-13 Suntory Ltd 安定化された生理活性物質製剤
CA1340597C (en) * 1984-08-27 1999-06-22 Haim Aviv Expression vectors containing pl promoter, and engineered restriction site for convenient replacement of ribosomal binding site, plasmids containing the vectors, hosts containing the plasmids and related methods
JPS61111690A (ja) * 1984-11-06 1986-05-29 Ube Ind Ltd 組換えdnaおよびその用途
CA1232850A (en) * 1985-01-17 1988-02-16 Albert D. Friesen Purification of superoxide dismutase
ES8800982A1 (es) * 1985-07-05 1987-12-01 Takeda Chemical Industries Ltd Un metodo para producir la enzima superoxido-dismutasa modificada con derivados de polietilenglicol y triazina.
DK402785D0 (da) * 1985-09-03 1985-09-03 Syn Tek Ab Fremgangsmaade til fremstilling af et enzym
JPS6279778A (ja) * 1985-10-04 1987-04-13 Suntory Ltd 新規ス−パ−オキシドデイスムタ−ゼ及びその製造方法
US5246847A (en) * 1985-11-22 1993-09-21 Bio-Technology General Corp. Polypeptide analogs of human manganese superoxide dismutase and compositions and complexes thereof
IE59498B1 (en) * 1985-11-22 1994-03-09 Bio Technology General Corp Human manganese superoxide dismutase analog, plasmid for its expression and method of recovering it in enzymatically active form
US4933433A (en) * 1986-01-31 1990-06-12 E. I. Du Pont De Nemours And Company Recombinant interleukin-2 composition and process for making it
US5260204A (en) * 1987-03-14 1993-11-09 Boehringer Ingelheim International Gmbh Human manganese superoxide dismutase (hMn-SOD)
EP0284105B1 (en) * 1987-03-27 1995-11-15 Bio-Technology General Corporation Human manganese superoxide dismutase and methods of treatment
DE3851257D1 (de) * 1987-05-21 1994-10-06 Suntory Ltd Azyliertes Derivat von Superoxid-Dismutase und dieses enthaltende Zusammensetzung.
US4895716A (en) * 1987-06-09 1990-01-23 Biogen, Inc. Stabilized formulations of gamma interferons
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
JPH01304882A (ja) * 1988-06-03 1989-12-08 Ube Ind Ltd ヒトCu,Zn型スーパーオキシドジスムターゼの安定保存法
WO1989012677A1 (en) * 1988-06-14 1989-12-28 Chiron Corporation Superoxide dismutase analogs having novel binding properties
JPH0610138B2 (ja) * 1988-07-12 1994-02-09 日本化薬株式会社 スーパーオキシドディスムターゼ組成物
US5538878A (en) * 1988-08-08 1996-07-23 Calgene, Inc. Superoxide dismutase expression in plants
EP0359617A3 (en) * 1988-09-02 1990-04-04 Plant Genetic Systems, N.V. Stress-tolerant plants
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
IL96136A (en) * 1989-11-07 2000-12-06 Bio Technology General Corp Use of hydrophobic chromatography in a method for purification of copper-zinc superoxide dismutase from cells containing same
JPH0568541A (ja) * 1990-12-28 1993-03-23 Asahi Chem Ind Co Ltd 活性なエクストラセルラー・スーパーオキシドジスムターゼの製造方法
US5298410A (en) * 1993-02-25 1994-03-29 Sterling Winthrop Inc. Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life

Also Published As

Publication number Publication date
AU5195393A (en) 1994-06-09
IL107754A0 (en) 1994-02-27
KR940011014A (ko) 1994-06-20
IL107754A (en) 1996-10-16
PH30788A (en) 1997-10-17
EP0599262A2 (de) 1994-06-01
NZ250285A (en) 1995-04-27
HU9303365D0 (en) 1994-03-28
MX9307433A (es) 1994-08-31
FI935264A (fi) 1994-05-28
AU671495B2 (en) 1996-08-29
NO934289L (no) 1994-05-30
EP0599262A3 (de) 1994-11-23
DE4239877C1 (de) 1994-03-17
FI935264A0 (fi) 1993-11-26
US5464614A (en) 1995-11-07
ZA938848B (en) 1995-04-06
HUT65580A (en) 1994-07-28
JPH06199691A (ja) 1994-07-19
NO934289D0 (no) 1993-11-26
CA2110087A1 (en) 1994-05-28

Similar Documents

Publication Publication Date Title
DK0634000T3 (pl)
DK0652790T3 (pl)
DK0613608T3 (pl)
DK0551248T3 (pl)
DK0630289T3 (pl)
DK0599160T3 (pl)
TW252046B (pl)
DK0553681T3 (pl)
DK0581129T3 (pl)
DK0571874T3 (pl)
DK0564197T3 (pl)
DK0581726T3 (pl)
DK0576097T3 (pl)
BR9202713C1 (pl)
DK0590732T3 (pl)
FR2688884B1 (pl)
AU631518B2 (pl)
BRPI9204323A2 (pl)
AU2098792A (pl)
AU1842892A (pl)
CN3014183S (pl)
AU2840792A (pl)
AU2527392A (pl)
AU633800B1 (pl)
AU633801B1 (pl)